Last reviewed · How we verify
Blenrep
At a glance
| Generic name | Blenrep |
|---|---|
| Sponsor | Duke University |
| Target | Low affinity immunoglobulin gamma Fc region receptor III-A, High affinity immunoglobulin gamma Fc receptor I, IgG receptor FcRn large subunit p51 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Multiple myeloma
- Relapse multiple myeloma
Common side effects
- Reduction in BCVA
- Corneal exam findings
- Blurred vision
- Dry eye
- Photophobia
- Foreign body sensation in eyes
- Eye irritation
- Upper respiratory tract infection
- Hepatotoxicity
- Eye pain
- Diarrhea
- Fatigue
Serious adverse events
- Pneumonia
- Pyrexia
- Thrombocytopenia
- COVID-19
- Upper respiratory tract infection
- Sepsis
- Second primary malignancy
- Anemia
- Respiratory failure
- Intracranial hemorrhage
Key clinical trials
- Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma (PHASE2)
- Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients (PHASE2)
- Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant (PHASE2)
- A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma (PHASE2)
- Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma (PHASE2)
- Selinexor and Backbone Treatments of Multiple Myeloma Patients (PHASE1, PHASE2)
- Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma (PHASE2)
- Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Blenrep CI brief — competitive landscape report
- Blenrep updates RSS · CI watch RSS
- Duke University portfolio CI